Novel drug OMS103HP reduces pain and improves joint motion and function for 90 days after arthroscopic meniscectomy

Arthroscopy - Journal of Arthroscopic and Related Surgery

Volumn 27, Issue 8, 2011, Pages

  Garrett, William E ^a   Kaeding, Christopher C ^b   ElAttrache, Neal S ^c   Xerogeanes, John W ^d   Hewitt, Michael S ^e   Skrepnik, Nebojsa V ^f   Papilion, John D ^g   O'Donnell, John B ^h   Fox, David L ⁱ   Ruvuna, Francis ^j   Whitaker, J Steven ^k   Demopulos, Gregory A ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Kerlan Jobe Orthopaedic Foundation   (United States)

^d Emory Spine Center   (United States)

^e Orthopedic Physicians of Colorado   (United States)

^f Tucson Orthopaedic Institute   (United States)

^g JDP Medical Research   (United States)

^h Greater Chesapeake Orthopaedic Associates   (United States)

ⁱ Northeast Orthopedics and Sports Medicine   (United States)

^j Cyberonics Inc   (Italy)

^k OMEROS CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; OMS 103 HP; RINGER LACTATE SOLUTION; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; ARTHROSCOPIC SURGERY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; JOINT FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENISCECTOMY; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RECOVERY ROOM; SELF REPORT; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79960934726     PISSN: 07498063     EISSN: 15263231     Source Type: Journal    
DOI: 10.1016/j.arthro.2011.02.038     Document Type: Article

References (45)

1. Pedowitz RA, O'Connor JJ. Daniel's knee injuries: Ligament and cartilage structure, function, injury, and repair. Philadelphia: Lippincott, Williams & Wilkins, 2002.
2. Freeman TA, Parvizi J, Della Valle CJ, Steinbeck MJ. Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair 2009;2:5-16.
3. Murakami S, Muneta T, Furuya K, et al. Immunohistologic analysis of synovium in infrapatellar fat pad after anterior cruciate ligament injury. Am J Sports Med 1995;23:763-768.
4. Dirig DM, Yaksh TL. Spinal synthesis and release of prostanoids after peripheral injury and inflammation. Adv Exp Med Biol 1999;469:401-408.
5. Millan MJ. The induction of pain: An integrative review. Prog Neurobiol 1999;57:1-164. (Pubitemid 28551764)
6. Dray A. Pharmacology of peripheral afferent terminals. In: Yaksh TL, Lynch C III, Zapol WM, Maze M, Biebuyck JF, Saidman LJ, eds. Anesthesia: Biologic foundations. Philadelphia: Lippincott-Raven, 1997;543-556.
7. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease- activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001;22:146-152. (Pubitemid 32181845)
8. McMahon SB, Bennett DHL. Growth factors and pain. Handb Exp Pharmacol 1997;130:135-154.
9. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;43:1916-1926.
10. Cuellar JM, Scuderi GJ, Cuellar VG, Golish SR, Yeomans DC. Diagnostic utility of cytokine biomarkers in the evaluation of acute knee pain. J Bone Joint Surg Am 2009;91:2313-2320.
11. Reuben SS, Bhopatkar S, Maciolek H, Joshi W, JS. The preemptive effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002;94:55-59.
12. Irie K, Uchiyama E, Iwaso H. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 2003;10:93-96. (Pubitemid 36324521)
13. Darabos N, Hundric-Haspl Z, Haspl M, et al. Correlation between synovial fluid and serum IL-1β levels after ACL surgery-preliminary report. Int Orthop 2009;33:413-418.
14. Cameron M, Buchgraber A, Passler H, et al. The natural history of the anterior cruciate ligament-deficient knee: Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med 1997;26:751-754. (Pubitemid 27508409)
15. Tang Z, Yang L, Wang Y, et al. Contributions of different intraarticular tissues to the acute phase elevation of synovial fluid MMP-2 following rat ACL rupture. J Orthop Res 2009; 21:243-248.
16. Kawaguchi A, Nakaya H, Okabe T, et al. Blocking of tumor necrosis factor activity promotes natural repair of osteochondral defects in rabbit knee. Acta Orthop 2008;80: 606-611.
17. Fox BA, Stephens MM. Treatment of knee osteoarthritis with Orthokine-derived autologous conditioned serum. Exp Rev Clin Immunol 2010;6:335-345.
18. McNulty AL, Weinberg JB, Guilak F. Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus. Clin Orthop Relat Res 2009;267:1557-1567.
19. Grishko V, Xu M, Wilson G, Pearsall AW IV. Apoptosis and mitochondrial dysfunction in human chondrocytes following exposure to lidocaine, bupivacaine, and ropivacaine. J Bone Joint Surg Am 2010;92:609-618.
20. Takeno K, Kobayashi S, Miyazaki T, et al. Lidocaine cytotoxicity to the zygapophysial joints in rabbits: Changes in cell viability and proteoglycan metabolism in vitro. Spine 2009;34:E945-E951.
21. Rapley JH, Beavis RC, Barber FA. Glenohumeral chondrolysis after shoulder arthroscopy associated with continuous bupivacaine infusion. Arthroscopy 2009;25:1367-1373.
22. Chu CR, Izzo NJ, Papas NE, Fu FH. In vitro exposure to 0.5% bupivacaine is cytotoxic to bovine articular chondrocytes. Arthroscopy 2006;22:693-699.
23. Chu CR, Izzo NJ, Coyle CH, Papas NE, Logar A. The in vitro effects of bupivacaine on articular chondrocytes. J Bone Joint Surg Br 2008;90:814-820. (Pubitemid 351859815)
24. Karpie JC, Chu CR. Lidocaine exhibits dose- and time-dependent cytotoxic effects on bovine articular chondrocytes in vitro. Am J Sports Med 2007;35:1621-1627.
25. Fanton GS, Dillingham MF, Wall MS, et al. Novel drug product to improve joint motion and function and reduce pain after arthroscopic anterior cruciate ligament reconstruction. Arthroscopy 2008;24:625-636.
26. Martinez RV, Reval M, Campos MD, et al. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol 2002;54:405-412. (Pubitemid 34232341)
27. Mazario J, Gaitan G, Herrero JF. Cyclooxygenase-1 vs. cyclooxygenase- 2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology 2001;40:937-946. (Pubitemid 32510807)
28. Torres-Lopez JE, Ortiz MI, Castaneda-Hernandez G, et al. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 2002;70:1669-1676. (Pubitemid 34178374)
29. Mauleon D, Artigas R, Garcia ML, Carganico G. Preclinical and clinical development of dexketoprofen. Drugs 1996;52: 24-45 (Suppl 5).
30. Daffonchio L, Rossoni G, Clavenna G, Omini C, Berti F. Protective activity of ketoprofen lysine salt against the pulmonary effects induced by bradykinin in guinea-pigs. Inflamm Res 1996;45:259-264. (Pubitemid 26159999)
31. Maling HM, Webster ME, Williams MA, Saul W, Anderson W. Inflammation induced by histamine, serotonin, bradykinin and compound 48-80 in the rat: Antagonists and mechanisms of action. J Pharmacol Exp Ther 1974;191:300-310.
32. Pierce PA, Xie GX, Peroutka SJ, Green PG, Levine JD. 5-Hydroxytryptamine- induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. J Pharmacol Exp Ther 1995;275:502-508.
33. Hatanaka K, Nomura T, Hidaka K, et al. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology 1996;35:1621-1626. (Pubitemid 27026491)
34. Hall H, Ogren SO. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 1981;70:393-407. (Pubitemid 11149331)
35. Bernstein JE, Whitney DH, Soltani K. Inhibition of histamine induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol 1981;5:582-585. (Pubitemid 12221170)
36. Lefkowitz RJ, Hoffman BB, Taylor P. Neurotransmission: The autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The pharmacological basis of therapeutics. Ed 10. New York: McGraw-Hill, 2001;116-154.
37. Watling KJ. The Sigma-RBI handbook of receptor classification and signal transduction. Ed 4. Natick, MA: Sigma-RBI, 2001.
38. Law H, Dukat M, Teitler M, et al. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: A structure-affinity investigation. J Med Chem 1998;41:2243-2251. (Pubitemid 28285726)
39. Molderings GJ, Werner K, Likungu J, Gothert M. Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5 HT 1D subtype. Naunyn Schmiedebergs Arch Pharmacol 1990;342:371-377. (Pubitemid 20284117)
40. Reddy SV, Maderdrut JL, Yaksh TL. Spinal cord pharmacology of adrenergic agonist-mediated antinociception. J Pharmacol Exp Ther 1980;213:525-533. (Pubitemid 10085156)
41. Sherman SE, Loomis CW, Milne B, Cervenko FW. Tolerance to intrathecal oxymetazoline induced analgesia, with paradigm- dependent cross-tolerance to intrathecal morphine. J Pharmacol Exp Ther 1988;245:319-326.
42. Loomis CW, Vyas D, Sherman SE. Intrathecal oxymetazoline does not produce neurotoxicity in the spinal cord of the rat. Brain Res 1992;599:73-82. (Pubitemid 23024919)
43. American Society of Anesthesiologists. ASA Relative Value Guide. Park Ridge, IL: American Society of Anesthesiologists, 1995-2010. ASA Physical Status Classification System. Available from: http://www.asahq.org/For-Members/ Clinical-Information/ASAPhysical- Status-Classification-System.aspx. Accessed December 13, 2010.
44. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee injury and Osteoarthritis Outcome Score (KOOS)- Development of a self-administered outcome measure. J Orthop Sports Phys Ther 1998;28:88-96. (Pubitemid 28366508)
45. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): From joint injury to osteoarthritis. Health Qual Life Outcomes 2003;1:64.